newsfilter
← Latest News
Business Wire·

AlloVir Reports Third Quarter 2022 Financial Results

Posoleucel Continues to Advance in Three Ongoing Multi-National Phase 3 Registrational Trials Final Data Presentation from Posoleucel Phase 2 Multi-Virus Prevention Study by Year-End Company to Host Investor Webcast